Skip to content
MarketScale
‹ Back to IndustriesHealthcare

2020’s Impact on the Broadband Fiber Landscape

While broadband fiber may not be something the average consumer thinks much about, it has a great impact on all of our day-to-day lives. Unfortunately, high-speed internet is something many of us take for granted. No one knows this more than Kevin Morgan, Chief Marketing Officer for Clearfield. Host Shelby Skrhak had the opportunity to…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

While broadband fiber may not be something the average consumer thinks much about, it has a great impact on all of our day-to-day lives. Unfortunately, high-speed internet is something many of us take for granted.

No one knows this more than Kevin Morgan, Chief Marketing Officer for Clearfield. Host Shelby Skrhak had the opportunity to pick Morgan’s brain on a “state of the union” of sorts for fiber deployment across the country and, more specifically, rural broadband fiber.

For almost a decade, Morgan has been a seasoned advocate for broadband infrastructure and initiatives. While Morgan has always been thrilled to work at Clearfield, where he focuses on removing the barriers to fiber deployment, he feels that the tragic events of 2020 really showed the importance of the problems he is trying to solve.

“This year in particular, in 2020, has been the most bizarre, challenging year in history in terms of communications. The entire economy is shut down, we came back, we’ve been in quarantine, and, all along the way, we’ve seen evidence of what a broadband connection really means to people in their homes and their businesses,” Morgan said.

He went on to explain that the broadband used today is much different than it was even three years ago. “We were anticipating that this demand, this amount of broadband that was needed by the public, was going to come over the period of a number of years. When March hit in 2020, all of that demand accelerated right up to the present time,” Morgan said.

He explained that, because so many people utilized broadband connections to work, for distance learning and to receive medical care via telehealth, 2020 really illustrated the importance of breaking down broadband barriers.

“The ability to be diagnosed and talk to your doctor remotely over a video link, something that was far-fetched just a few years ago is reality today. So, these things make a huge difference, and the role that fiber optics plays in providing those broadband connections is undeniably the best of all the types of technologies out there,” Morgan said.

For deeper insight into the current state and future of fiber-fed broadband, tune in to the latest episode of Better Broadband.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512